# Organon & Co.: financial statements, quarterly

OGN · NYSE · CIK 1821825 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ogn.md) · [Financials](/companies/ogn/financials.md) · [Filings](/companies/ogn/filings.md) · [Insiders](/companies/ogn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ogn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,598 d](/filings/0001628280-26-011125.md) | [1,622](/filings/0001821825-25-000023.md) | [1,607](/filings/0001821825-25-000066.md) | [1,582](/filings/0001628280-25-050795.md) | [1,592 d](/filings/0001628280-26-011125.md) | [1,513](/filings/0001628280-26-029532.md) | [1,594](/filings/0001628280-26-051230.md) | [1,602](/filings/0001821825-26-000004.md) | [1,507 d](/filings/0001628280-26-011125.md) | [1,460](/filings/0001628280-26-029532.md) | [1,558](/filings/0001628280-26-051230.md) | [1,574](/filings/0001821825-26-000004.md) |
| Cost of revenue | $m | [683 d](/filings/0001628280-26-011125.md) | [665](/filings/0001821825-25-000023.md) | [668](/filings/0001821825-25-000066.md) | [659](/filings/0001628280-25-050795.md) | [696 d](/filings/0001628280-26-011125.md) | [672](/filings/0001628280-26-029532.md) | [720](/filings/0001628280-26-051230.md) | [745](/filings/0001821825-26-000004.md) | [766 d](/filings/0001628280-26-011125.md) | [677](/filings/0001628280-26-029532.md) | [711](/filings/0001628280-26-051230.md) | [705](/filings/0001821825-26-000004.md) |
| Gross profit | $m | [915 d](/filings/0001628280-26-011125.md) | [957](/filings/0001821825-25-000023.md) | [939](/filings/0001821825-25-000066.md) | [923](/filings/0001628280-25-050795.md) | [896 d](/filings/0001628280-26-011125.md) | [841](/filings/0001628280-26-029532.md) | [874](/filings/0001628280-26-051230.md) | [857](/filings/0001821825-26-000004.md) | [741 d](/filings/0001628280-26-011125.md) | [783](/filings/0001628280-26-029532.md) | [847](/filings/0001628280-26-051230.md) | [869](/filings/0001821825-26-000004.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [469 d](/filings/0001628280-26-011125.md) | [431](/filings/0001821825-25-000023.md) | [437](/filings/0001821825-25-000066.md) | [422](/filings/0001628280-25-050795.md) | [470 d](/filings/0001628280-26-011125.md) | [420](/filings/0001628280-26-029532.md) | [453](/filings/0001628280-26-051230.md) | [415](/filings/0001821825-26-000004.md) | [433 d](/filings/0001628280-26-011125.md) | [424](/filings/0001628280-26-029532.md) | [434](/filings/0001628280-26-051230.md) | [421](/filings/0001821825-26-000004.md) |
| Interest expense | $m | [129 d](/filings/0001628280-26-011125.md) | [131](/filings/0001821825-25-000023.md) | [131](/filings/0001821825-25-000066.md) | [126](/filings/0001628280-25-050795.md) | [132 d](/filings/0001628280-26-011125.md) | [124](/filings/0001628280-26-029532.md) | [131](/filings/0001628280-26-051230.md) | [128](/filings/0001821825-26-000004.md) | [121 d](/filings/0001628280-26-011125.md) | [111](/filings/0001628280-26-029532.md) | [108](/filings/0001628280-26-051230.md) | [106](/filings/0001821825-26-000004.md) |
| Income tax | $m | [(442) d](/filings/0001628280-26-011125.md) | [35.0](/filings/0001821825-25-000023.md) | [40.0](/filings/0001821825-25-000066.md) | [(152)](/filings/0001628280-25-050795.md) | [20.0 d](/filings/0001628280-26-011125.md) | [14.0](/filings/0001628280-26-029532.md) | [84.0](/filings/0001628280-26-051230.md) | [83.0](/filings/0001821825-26-000004.md) | [57.0 d](/filings/0001628280-26-011125.md) | [67.0](/filings/0001628280-26-029532.md) | [75.0](/filings/0001628280-26-051230.md) | [91.0](/filings/0001821825-26-000004.md) |
| Net income | $m | [546 d](/filings/0001628280-26-011125.md) | [201](/filings/0001821825-25-000023.md) | [195](/filings/0001821825-25-000066.md) | [359](/filings/0001628280-25-050795.md) | [109 d](/filings/0001628280-26-011125.md) | [87.0](/filings/0001628280-26-029532.md) | [145](/filings/0001628280-26-051230.md) | [160](/filings/0001821825-26-000004.md) | [(205) d](/filings/0001628280-26-011125.md) | [146](/filings/0001628280-26-029532.md) | [108](/filings/0001628280-26-051230.md) | [164](/filings/0001821825-26-000004.md) |
| Diluted EPS | $ per share | not reported | [0.78](/filings/0001821825-25-000023.md) | [0.75](/filings/0001821825-25-000066.md) | [1.38](/filings/0001628280-25-050795.md) | not reported | [0.33](/filings/0001628280-26-029532.md) | [0.56](/filings/0001628280-26-051230.md) | [0.61](/filings/0001821825-26-000004.md) | not reported | [0.55](/filings/0001628280-26-029532.md) | [0.40](/filings/0001628280-26-051230.md) | [0.60](/filings/0001821825-26-000004.md) |
| Basic EPS | $ per share | not reported | [0.78](/filings/0001821825-25-000023.md) | [0.76](/filings/0001821825-25-000066.md) | [1.39](/filings/0001628280-25-050795.md) | not reported | [0.34](/filings/0001628280-26-029532.md) | [0.56](/filings/0001628280-26-051230.md) | [0.61](/filings/0001821825-26-000004.md) | not reported | [0.56](/filings/0001628280-26-029532.md) | [0.41](/filings/0001628280-26-051230.md) | [0.62](/filings/0001821825-26-000004.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.7](/filings/0001104659-25-108693.md) | [0.6](/filings/0001821825-24-000056.md) | [0.7](/filings/0001821825-24-000083.md) | [0.8](/filings/0001821825-24-000108.md) | [0.7](/filings/0001628280-26-011125.md) | [0.5](/filings/0001821825-25-000023.md) | [0.6](/filings/0001821825-25-000066.md) | [0.7](/filings/0001628280-25-050795.md) | [0.6](/filings/0001821825-26-000004.md) | [1.1](/filings/0001628280-26-029532.md) | [1.1](/filings/0001628280-26-051230.md) | [1.5](/filings/0001821825-26-000004.md) |
| Current assets | $bn | [4.5](/filings/0001104659-25-108693.md) | [4.2](/filings/0001821825-24-000056.md) | [4.5](/filings/0001821825-24-000083.md) | [4.8](/filings/0001821825-24-000108.md) | [4.3](/filings/0001628280-26-011125.md) | [4.4](/filings/0001821825-25-000023.md) | [4.6](/filings/0001821825-25-000066.md) | [4.7](/filings/0001628280-25-050795.md) | [4.4](/filings/0001821825-26-000004.md) | [4.9](/filings/0001628280-26-029532.md) | [5.1](/filings/0001628280-26-051230.md) | [5.4](/filings/0001821825-26-000004.md) |
| Total assets | $bn | [12.1](/filings/0001104659-25-108693.md) | [11.9](/filings/0001821825-24-000056.md) | [12.2](/filings/0001821825-24-000083.md) | [12.8](/filings/0001821825-24-000108.md) | [13.1](/filings/0001628280-26-011125.md) | [13.2](/filings/0001821825-25-000023.md) | [13.5](/filings/0001821825-25-000066.md) | [13.6](/filings/0001628280-25-050795.md) | [12.9](/filings/0001821825-26-000004.md) | [13.0](/filings/0001628280-26-029532.md) | [13.2](/filings/0001628280-26-051230.md) | [13.4](/filings/0001821825-26-000004.md) |
| Current liabilities | $bn | [2.9](/filings/0001104659-25-108693.md) | [2.5](/filings/0001821825-24-000056.md) | [2.8](/filings/0001821825-24-000083.md) | [2.8](/filings/0001821825-24-000108.md) | [2.7](/filings/0001628280-26-011125.md) | [2.6](/filings/0001821825-25-000023.md) | [2.8](/filings/0001821825-25-000066.md) | [2.7](/filings/0001628280-25-050795.md) | [2.4](/filings/0001821825-26-000004.md) | [2.5](/filings/0001628280-26-029532.md) | [2.6](/filings/0001628280-26-051230.md) | [2.7](/filings/0001821825-26-000004.md) |
| Total liabilities | $bn | [12.1](/filings/0001104659-25-108693.md) | [11.8](/filings/0001821825-24-000056.md) | [12.0](/filings/0001821825-24-000083.md) | [12.3](/filings/0001821825-24-000108.md) | [12.6](/filings/0001628280-26-011125.md) | [12.6](/filings/0001821825-25-000023.md) | [12.8](/filings/0001821825-25-000066.md) | [12.6](/filings/0001628280-25-050795.md) | [12.1](/filings/0001821825-26-000004.md) | [12.1](/filings/0001628280-26-029532.md) | [12.2](/filings/0001628280-26-051230.md) | [12.2](/filings/0001821825-26-000004.md) |
| Long-term debt | $bn | [8.8](/filings/0001104659-25-108693.md) | [8.7](/filings/0001821825-24-000056.md) | [8.6](/filings/0001821825-24-000083.md) | [8.7](/filings/0001821825-24-000108.md) | [8.9](/filings/0001628280-26-011125.md) | [8.9](/filings/0001821825-25-000023.md) | [8.8](/filings/0001821825-25-000066.md) | [8.8](/filings/0001628280-25-050795.md) | [8.6](/filings/0001821825-26-000004.md) | [8.6](/filings/0001628280-26-029532.md) | [8.5](/filings/0001628280-26-051230.md) | [8.5](/filings/0001821825-26-000004.md) |
| Current portion of debt | $bn | [0.0](/filings/0001104659-25-108693.md) | [0.0](/filings/0001821825-24-000056.md) | [0.0](/filings/0001821825-24-000083.md) | [0.0](/filings/0001821825-24-000108.md) | [0.0](/filings/0001104659-25-108693.md) | [0.0](/filings/0001821825-25-000023.md) | [0.1](/filings/0001821825-25-000066.md) | [0.0](/filings/0001628280-25-050795.md) | [0.0](/filings/0001821825-26-000004.md) | [0.0](/filings/0001628280-26-029532.md) | [0.1](/filings/0001628280-26-051230.md) | [0.1](/filings/0001821825-26-000004.md) |
| Shareholders' equity | $bn | [(0.1)](/filings/0001628280-26-011125.md) | [0.0](/filings/0001821825-25-000066.md) | [0.1](/filings/0001628280-25-050795.md) | [0.5](/filings/0001628280-25-050795.md) | [0.5](/filings/0001821825-26-000004.md) | [0.5](/filings/0001628280-26-051230.md) | [0.7](/filings/0001821825-26-000004.md) | [0.9](/filings/0001821825-26-000004.md) | [0.8](/filings/0001821825-26-000004.md) | [0.9](/filings/0001628280-26-051230.md) | [1.0](/filings/0001821825-26-000004.md) | [1.2](/filings/0001821825-26-000004.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent, us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [397 d](/filings/0001628280-26-011125.md) | [76.0](/filings/0001821825-25-000023.md) | [332 d](/filings/0001821825-25-000066.md) | [141 d](/filings/0001628280-25-050795.md) | [390 d](/filings/0001628280-26-011125.md) | [75.0](/filings/0001628280-26-029532.md) | [220 d](/filings/0001628280-26-051230.md) | [264 d](/filings/0001821825-26-000004.md) | [141 d](/filings/0001628280-26-011125.md) | [225](/filings/0001628280-26-029532.md) | [107 d](/filings/0001628280-26-051230.md) | [370 d](/filings/0001821825-26-000004.md) |
| Capital expenditure | $m | [79.0 d](/filings/0001628280-26-011125.md) | [46.0](/filings/0001821825-25-000023.md) | [32.0 d](/filings/0001821825-25-000066.md) | [42.0 d](/filings/0001628280-25-050795.md) | [55.0 d](/filings/0001628280-26-011125.md) | [32.0](/filings/0001628280-26-029532.md) | [39.0 d](/filings/0001628280-26-051230.md) | [46.0 d](/filings/0001821825-26-000004.md) | [45.0 d](/filings/0001628280-26-011125.md) | [37.0](/filings/0001628280-26-029532.md) | [42.0 d](/filings/0001628280-26-051230.md) | [44.0 d](/filings/0001821825-26-000004.md) |
| Dividends paid | $m | [73.0 d](/filings/0001628280-26-011125.md) | [70.0](/filings/0001821825-25-000023.md) | [79.0 d](/filings/0001821825-25-000066.md) | [74.0 d](/filings/0001628280-25-050795.md) | [74.0 d](/filings/0001628280-26-011125.md) | [71.0](/filings/0001628280-26-029532.md) | [10.0 d](/filings/0001628280-26-051230.md) | [3.0 d](/filings/0001821825-26-000004.md) | [4.0 d](/filings/0001628280-26-011125.md) | [5.0](/filings/0001628280-26-029532.md) | [6.0 d](/filings/0001628280-26-051230.md) | [5.0 d](/filings/0001821825-26-000004.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [256](/filings/0001821825-24-000056.md) | [256](/filings/0001821825-24-000083.md) | [256](/filings/0001821825-24-000108.md) | [258](/filings/0001821825-25-000023.md) | [259](/filings/0001821825-25-000066.md) | [260](/filings/0001628280-25-050795.md) | [261](/filings/0001628280-26-029532.md) | [260](/filings/0001628280-26-051230.md) | [261](/filings/0001821825-26-000004.md) | [263](/filings/0001628280-26-029532.md) | [270](/filings/0001628280-26-051230.md) | [272](/filings/0001821825-26-000004.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 262,621,584 at 2026-10-23, from the cover of the [10-Q filed 2026-10-30](/filings/0001821825-26-000004.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 31, 2026, 03:06 ET. No prices; not investment advice.